arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Abstract submission

We like to thank the many collegues who worked so hard for ANR2020 by submitting abstracts and acting as reviewers. We hope to keep you on board for ANR2021. As the postponed meeting will only take place one year from now and to ensure to capture the most recent developments in neuroblastoma research, we decided that we will organize a new abstract round. Unfortunately, we have to abrogate the current abstract selection process for the cancelled ANR2020 meeting. More information about the abstract submission for ANR2021 will follow shortly.

Abstract Guidelines
The abstract submission guidelines of the ANR2021 meeting are intended to provide clear instructions for submitting an abstract. You are kindly requested to carefully read the guidelines below before starting the submission process.

 General abstract submission guidelines

  1. Abstracts can only be submitted online via the abstract submission form. Abstracts sent by post or email will not be accepted. No exception will be made.
  2. The content of the abstract must be related to one of the topics listed below*. If you feel your abstract does not fall in any of the topic, but relevant for ANR meeting, send a letter with justification to congress secretariat: anr2020@congresscare.com. Your abstract may be considered.
  3. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.
  4. For standardization, the acceptable length of the abstract is a maximum of 500 words.
  5. After the submission deadline it is not possible to make any changes.
  6. Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.
  7. Individuals may be the first author of more than one abstract.
  8. The presenting author of the abstract must be registered for the meeting.

Abstract Format and Content

  • All mandatory fields must be filled out.
  • Abstracts must not exceed more than 500 words. The system will inform you if you exceed the word limit.
  • Please use the following headings in your abstract so that the Scientific Committee can evaluate the quality and completeness of your abstract
  • Background / introduction
  • Aims
  • Methods / materials
  • Results
  • Summary / conclusion

Presentation preference

  • Oral Presentation
    will range from 10 to 15 minutes length for abstracts integrated in general sessions. Presenting authors should use slides to accompany their presentation. Any abstracts in the presidential sessions will be invited at the discretion of the Scientific Committee. If your abstract is selected as an oral presentation, authors will be eligible for the best oral prize.
  • Rapid Fire Presentation
    During the Rapid Fire sessions the Scientific Committee provides you the possibility to present your work during a one slide presentation during one minute.
  • Traditional Poster
    if your abstract is selected as an poster during the ANR2020 meeting we will ask the first authors to make themselves available during the breaks and lunch to answer questions from the audience and Scientific Committee regarding the poster. Should a first author be unable to be present on-site, then a co-author should be asked to take over. As first author you will be eligible for the best poster prize.

Topics

Mark the congress highlight which best fits with your abstract content (if none of the 7 topics apply: mark “other”)

*This information will guide us for allocating abstracts to particular sessions.

• Neuroblastoma as developmental disease
o basic
o translational
o clinical

• Targeted therapy: ALK and other targets in personalized medicine
o basic
o translational
o clinical

• Progress in treatment and challenges for preclinical studies
o basic
o translational
o clinical

• A deeper look into neuroblastoma tumor heterogeneity and clinical behaviour
o basic
o translational
o clinical

• Neuroblastoma tumour biology and omics: from bench to the clinic
o basic
o translational
o clinical

• Gene regulatory networks and epigenetics: from basic science to therapy
o basic
o translational
o clinical

• Progress and hurdles in immune therapy of neuroblastoma
o basic
o translational
o clinical

• Other
o basic
o translational
o clinical